Schering-Plough Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Schering-Plough Corporation for the period ended September 30, 2007. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. A primary strategic focus during this period was the preparation for the planned acquisition of Organon BioSciences N.V. for approximately €11.0 billion, expected to close by the end of 2007.
Key Financial Metrics (Nine Months Ended Sept 30, 2007)
| Metric | 2007 (9 Months) | 2006 (9 Months) |
|---|---|---|
| Net Sales | $8,965 million | $7,944 million |
| Net Income | $1,853 million | $940 million |
| Net Income Available to Common Shareholders | $1,773 million | $875 million |
| Diluted EPS | $1.15 | $0.59 |
| Operating Cash Flow | $1,248 million | $1,515 million |
| Cash and Cash Equivalents (End of Period) | $12,366 million | $2,574 million |
| Long-Term Debt | $4,403 million | $2,414 million |
| Gross Margin | 68.3% | 65.0% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% year-over-year, driven by strong performance in Prescription Pharmaceuticals (up 14%) and favorable foreign exchange impacts (3%). Key growth drivers included REMICADE (+32%), NASONEX (+19%), and TEMODAR (+22%).
- Profitability Surge: Net income more than doubled, primarily due to a significant increase in equity income from the Merck/Schering-Plough cholesterol joint venture (VYTORIN/ZETIA) and substantial mark-to-market gains on foreign currency options.
- Unusual Items:
- Foreign Currency Gains: The company recognized $289 million in mark-to-market gains on foreign currency options purchased to hedge the Organon acquisition. This is a non-operating, non-cash gain included in "Other income, net."
- Equity Income: Equity income from the cholesterol joint venture increased 40% to $1.483 billion, reflecting strong sales of VYTORIN and ZETIA.
- Expense Increases: Research and Development (R&D) expenses rose 33% to $2.071 billion, driven by increased clinical trial spending and $176 million in upfront licensing payments. SG&A expenses increased 11% due to higher promotional spending.
- Liquidity Transformation: Cash and cash equivalents increased by nearly $10 billion to $12.4 billion, resulting from massive financing activities (debt and equity issuances) to fund the Organon acquisition.
Guidance, Outlook, and Risks
- Acquisition Outlook: Management expects the Organon BioSciences transaction to close by year-end 2007. Financing is secured through existing cash, recent debt issuances (€2.0 billion in Oct 2007), and credit facilities.
- Product Outlook: Sales of VYTORIN and ZETIA are expected to continue growing in Q4 2007 and 2008. R&D expenses are expected to continue growing faster than adjusted net sales due to expanding Phase III clinical trials.
- Key Risks:
- Regulatory & Legal: Ongoing scrutiny regarding pricing practices (AWP litigation), government investigations (Massachusetts Investigation settlement paid $435 million), and patent challenges (Hatch-Waxman actions for Temodar, ZETIA, Clarinex).
- Product Dependence: Significant reliance on the cholesterol franchise (VYTORIN/ZETIA) and REMICADE. Competition from generics and new entrants poses a threat.
- Market Risk: Exposure to foreign currency fluctuations and interest rate changes, partially mitigated by hedging strategies.
Investor Verification Checklist
- Quality of Earnings: Verify the sustainability of net income by excluding the $289 million non-recurring mark-to-market gain on currency options.
- Acquisition Financing: Confirm the closing of the Organon BioSciences acquisition and the final debt/equity structure post-closing.
- Joint Venture Performance: Monitor sales trends of VYTORIN and ZETIA, as equity income from this venture is a critical profit driver not reflected in top-line net sales.
- Legal Contingencies: Review updates on the Massachusetts Investigation settlement, AWP litigation, and patent infringement suits regarding key products.
- R&D Pipeline: Assess the progress of Phase III trials for thrombin receptor antagonist, vicriviroc, and golimumab, given the significant increase in R&D spend.